Market closedNon-fractional
C4 Therapeutics/CCCC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About C4 Therapeutics
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
Ticker
CCCC
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Watertown, United States
Employees
145
Website
www.c4therapeutics.com
C4 Therapeutics Metrics
BasicAdvanced
$443M
Market cap
-
P/E ratio
-$2.31
EPS
3.11
Beta
-
Dividend rate
Price and volume
Market cap
$443M
Beta
3.11
Financial strength
Current ratio
5.082
Quick ratio
4.94
Long term debt to equity
24.92
Total debt to equity
26.994
Interest coverage (TTM)
-172.86%
Management effectiveness
Return on assets (TTM)
-20.86%
Return on equity (TTM)
-48.42%
Valuation
Price to revenue (TTM)
17.514
Price to book
1.71
Price to tangible book (TTM)
1.71
Price to free cash flow (TTM)
-3.775
Growth
Revenue change (TTM)
-26.34%
Earnings per share change (TTM)
-13.79%
3-year revenue growth (CAGR)
-16.00%
3-year earnings per share growth (CAGR)
-11.74%
What the Analysts think about C4 Therapeutics
Analyst Ratings
Majority rating from 8 analysts.
C4 Therapeutics Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$3M
-6.25%
Net income
-$28M
-18.44%
Profit margin
-943.33%
-13.01%
C4 Therapeutics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.73
-$0.55
-$0.70
-$0.41
-
Expected
-$0.69
-$0.66
-$0.68
-$0.35
-$0.37
Surprise
6.14%
-16.67%
2.56%
16.67%
-
C4 Therapeutics News
AllArticlesVideos
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
GlobeNewsWire·1 week ago
C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day
GlobeNewsWire·3 weeks ago
C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for C4 Therapeutics stock?
C4 Therapeutics (CCCC) has a market cap of $443M as of July 27, 2024.
What is the P/E ratio for C4 Therapeutics stock?
The price to earnings (P/E) ratio for C4 Therapeutics (CCCC) stock is 0 as of July 27, 2024.
Does C4 Therapeutics stock pay dividends?
No, C4 Therapeutics (CCCC) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next C4 Therapeutics dividend payment date?
C4 Therapeutics (CCCC) stock does not pay dividends to its shareholders.
What is the beta indicator for C4 Therapeutics?
C4 Therapeutics (CCCC) has a beta rating of 3.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell C4 Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.